Oncorena develops a completely new and potentially revolutionizing treatment for patients with metastatic kidney cancer. The drug is based on the natural substance orellanine, found in certain mushrooms known to cause kidney damage to persons who eat them.In experiments we have demonstrated that orellanine kills also kidney cancer cells and this will now be verified in patients.
Impact: New treatment for metastasized renal cancer
Impact: New treatment for metastasized renal cancer
Location: Sweden, Lund
Total raised: $2.65M
Investors 1
| Date | Name | Website |
| - | GU Venture... | guventures... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| - | - | $2.65M | - |
Mentions in press and media 13
| Date | Title | Description |
| 26.06.2025 | Oncorena’s new issue of shares fully subscribed | Oncorena’s new issue of shares fully subscribed Thu, Jun 26, 2025 08:30 CET Report this content Lund June 26, 2025 – Today, Oncorena communicates that the new issue of shares was fully subscribed to a sum of 133 million SEK (US$ 13.9M). The... |
| 18.03.2025 | Oncorena receives FDA approval to initiate studies in the US | Oncorena receives FDA approval to initiate studies in the US Tue, Mar 18, 2025 08:15 CET Report this content Lund, Sweden, March 18, 2025 - Oncorena is pleased to announce that the FDA has approved the Company’s IND application to initiate ... |
| 04.09.2023 | Oncorena’s First Patient Treated with ONC175 (orellanine) in clinial phase I/II trial in Patients with Metastatic Renal Cancer and Dialysis at Karolinska University Hospital in Stockholm, Sweden | Oncorena’s First Patient Treated with ONC175 (orellanine) in clinial phase I/II trial in Patients with Metastatic Renal Cancer and Dialysis at Karolinska University Hospital in Stockholm, Sweden Mon, Sep 04, 2023 09:40 CET Report this conte... |
| 20.06.2022 | Börje Haraldsson appointed CEO of Oncorena AB | Börje Haraldsson appointed CEO of Oncorena AB Mon, Jun 20, 2022 08:30 CET Report this content LUND, SWEDEN, June 20, 2022 – Oncorena AB, which is developing a new and potentially groundbreaking treatment for patients with advanced kidney ca... |
| 01.02.2022 | Oncorena Initiates the Phase I-II Clinical Trial with Orellanine in Advanced Kidney Cancer Patients at Karolinska University Hospital in Sweden | Oncorena Initiates the Phase I-II Clinical Trial with Orellanine in Advanced Kidney Cancer Patients at Karolinska University Hospital in Sweden Tue, Feb 01, 2022 07:45 CET Report this content LUND, SWEDEN, February 1, 2022 – Oncorena today ... |
| 23.12.2021 | Oncorena Secures Financing of the Company's Continued Development of Orellanine, a Potential Breakthrough Therapy for Advanced Renal Cancer | LUND, Sweden, Dec. 23, 2021 /PRNewswire/ -- Oncorena, developing a potential breakthrough therapy for advanced renal cancer, receives a capital injection of MSEK 66 from one of the company's principal shareholders together with two new inve... |
| 23.12.2021 | Oncorena AB announced that it has received SEK 66 million in funding from Fahraeus Startup & Growth Ab, Linc AB, Odlander, Fredrikson & Co. AB | Oncorena AB announced that it has received SEK 66 million in funding on December 23, 2021. The transaction included participation from existing investor Odlander, Fredrikson & Co. AB and new investors Linc AB and Fahraeus Startup & ... |
| 23.12.2021 | Oncorena Secures Financing of the Company's Continued Development of Orellanine, a Potential Breakthrough Therapy for Advanced Renal Cancer | LUND, SWEDEN, December 23, 2021 - Oncorena, developing a potential breakthrough therapy for advanced renal cancer, receives a capital injection of MSEK 66 from one of the company's principal shareholders together with two new investors. Und... |
| 23.12.2021 | Oncorena Secures Financing of the Company’s Continued Development of Orellanine, a Potential Breakthrough Therapy for Advanced Renal Cancer | Oncorena Secures Financing of the Company’s Continued Development of Orellanine, a Potential Breakthrough Therapy for Advanced Renal Cancer Thu, Dec 23, 2021 07:30 CET LUND, SWEDEN, December 23, 2021 - Oncorena, developing a potential break... |
| - | HealthCap makes 104th investment as Swedish company Oncorena secures SEK 24m financing | Gothenburg, Sweden, September 29, 2016 Oncorena secures MSEK 24 for clinical studies of metastasized kidney cancer Oncorena Holding AB today announces that the company through a new share issue has secured capital to conduct clinical ... |
Show more